
Why MethaneSAT's Sudden Silence Should Concern Us All
Why Methane Matters
Methane is the second-most significant greenhouse gas after carbon dioxide, but it is far more potent in the short term, trapping over 80 times more heat than CO₂ over a 20-year period. It leaks from pipelines, fracking sites, livestock operations, and landfills, and plays a central role in accelerating global warming.
The total yearly methane (CH4) emissions from human activities expressed as weight in megatonnes ... More (Mt)
Unlike CO₂, however, methane breaks down relatively quickly in the atmosphere. That means cutting methane emissions is one of the fastest and most effective ways to reduce global temperatures in the near term.
Watch my short explainer video on how we can cut methane emissions—and why reducing short-lived climate pollutants like methane could help cool the planet by up to 0.5°C in just a few decades.
MethaneSAT was created to provide clear, independent, high-resolution data on where methane was leaking—and who was leaking it. It could single out individual oil fields and drill sites from orbit. And its early results were troubling: emissions from major oil and gas fields in North America and Central Asia were found to be several times higher than companies had officially reported.
What MethaneSAT Managed to Expose Before Falling Silent
A Sudden Silence
The satellite's loss of contact came without warning. According to EDF, the satellite likely experienced a power failure, possibly due to issues with its onboard thruster system or the effects of solar activity. It may never be recovered.
It's too early to draw conclusions. Space is inherently risky. But when a mission with this kind of potential—and this kind of impact—stops working just as it hits its stride, it raises difficult questions.
Was it just bad luck?
"I'm afraid they'll find a way to shut it down"Earlier this year, during a Zoom call to explore a potential collaboration between WeDontHaveTime.org and MethaneSAT, I spoke with a high-level executive involved in the mission. During our conversation, the person said bluntly that they feared the satellite could be shut down. "I'm afraid they'll find a way to shut it down," they told me. The satellite ultimately failed due to what appears to be a technical issue. But the fact that such a fear could be voiced at all—that a scientific mission could be seen as politically vulnerable—speaks volumes about the world we now live in.
A Broader Crisis in Climate Monitoring
MethaneSAT's loss is not an isolated event. Many of the world's most important Earth-observing satellites are aging rapidly. NASA's Terra, Aqua, and Aura satellites, launched in the early 2000s, are nearing the end of their operational lifespans. By the end of this decade, most of them will likely be decommissioned.
Yet there is no comprehensive replacement plan. Instead, U.S. political momentum is moving decisively in the opposite direction. The 2025 budget proposal from the House of Representatives includes dramatic cuts to Earth science programs at NASA and NOAA. These cuts threaten everything from climate monitoring to weather forecasting.
At the very moment we need more eyes on the planet, we're pulling the plug.
This week, every living NASA science chief—past and present—signed a joint letter opposing these cuts, warning that eliminating climate science capabilities at this stage would be 'flying blind into the storm.'
And the assault goes even deeper.
The Trump administration has also proposed shutting down the Mauna Loa Atmospheric Baseline Observatory, the lab that has measured atmospheric CO₂ continuously since 1958. This is the birthplace of the Keeling Curve—the iconic record that shows CO₂ rising from 313 parts per million to over 430 ppm today. It is the most conclusive, long-term evidence of human-caused climate change. And now, it too is on the chopping block.
If enacted, these proposals would eliminate much of the U.S. greenhouse gas monitoring network, from northern Alaska to the South Pole.
Transparency Under Threat
MethaneSAT's data was being integrated into broader climate tracking initiatives, such as Climate TRACE—a groundbreaking project backed by former Vice President Al Gore that aggregates real-time emissions data from satellites and AI-driven analysis. As I detailed in my previous Forbes article, Al Gore's Real-Time Climate Data Just Went Live—Here's Why It Matters, TRACE represents a revolutionary leap in emissions accountability. But the loss of MethaneSAT creates a critical gap in this otherwise powerful global emissions surveillance network.
The Fossil Gas Industry's Last Stand
The Methane Regulation is an EU law passed in 2024 aimed at reducing methane emissions in the energy sector, especially from oil, gas, and coal. While it came into force in 2024, rules for importers start applying gradually, and full compliance is expected by 2026–2027, depending on the provision.
Now, the European Commission is considering weakening the Methane Regulation, likely due to threats of tariffs coming from the Trump administration.
The regulation doesn't ban imports—it just says that if you want to sell gas or oil to the EU, you have to measure, report, and reduce your methane emissions. Pretty reasonable, right?
But now, of course, the fossil fuel industry shows up, teary-eyed, hat in hand, pleading for mercy.
In an open letter this week, industry reps said the regulation is too complicated, the timelines are too tight, and the compliance burden is just too heavy. They're asking for a grace period, contract protections, and a delay in enforcement. Why? Because it's hard, they say, to figure out exactly where their fuel came from or what the emissions were. Because some EU member states haven't finished their national rulebooks. Because compliance might cost money.
The fossil gas industry rakes in profits in the hundreds of billions of dollars every year. They've had plenty of time and capital to invest in tracking systems and cleaner infrastructure. Instead, many of them sat on the cash—or handed it out to shareholders—and now claim they're not ready.
This regulation didn't come out of nowhere. The warning signs were clear. The legislation process was long. The deadlines were known. Most infuriating of all, this regulation simply asks companies to do what any responsible, ethical organization would be doing of their own accord.
For decades, fossil fuel companies have externalized the cost of methane leakage—dumping a climate-damaging gas into the atmosphere while claiming their product is a clean 'bridge fuel.' This regulation is one of the first serious efforts to change that dynamic. It says: if you want access to the EU market, you have to take responsibility for your environmental footprint.
Powerful Interests at Stake
MethaneSAT's silence is undoubtedly welcomed by fossil fuel industries that stood to lose significantly from increased transparency and accountability. The disappearance of such detailed emissions data removes immediate pressure and scrutiny, allowing polluters to continue claiming to take action to curb emissions while doing nothing of the sort. Meanwhile, the planet's remaining carbon budget is rapidly running out.
What's Next?
We may never know exactly why MethaneSAT stopped transmitting. But its loss underscores a larger issue: our ability to monitor the Earth—our atmosphere, oceans, emissions—is being not just neglected, but deliberately defunded at a time when it should be rapidly expanding.
Imagine a hospital losing its ability to scan a patient mid-diagnosis. Doctors would be blind to the progression of the disease, unable to treat or even assess it. The loss of MethaneSAT is the climate equivalent. Without precise, reliable data, efforts to track and mitigate global warming risk becoming guesswork.
Meanwhile, critical climate infrastructure is being targeted elsewhere. The Trump administration's 2025 budget proposal seeks to shut down the Mauna Loa Atmospheric Baseline Observatory—home of the Keeling Curve and the longest-running CO₂ record in the world. It would also defund NOAA's broader greenhouse gas monitoring network, threatening continuity in our core climate records.
And yet, in just a few months of operation, MethaneSAT showed what's possible: near-real-time, high-resolution emissions data—independent, accessible, and globally impactful.
The response to its failure should not be retreat, but reinforcement.
Just because one satellite failed doesn't mean the mission failed. If anything, it proved how essential this kind of monitoring is.
New satellites must be launched. Not eventually—now.
Because we can't solve what we can't see.
And we should never accept flying blind as the new normal.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
42 minutes ago
- Associated Press
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 13, 2025-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ('Amylyx' or the 'Company') today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being evaluated in the pivotal Phase 3 LUCIDITY trial, led to a 64% least-squares (LS) mean reduction (p=0.0031) vs. baseline in the composite rate of Level 2 and Level 3 hypoglycemic events in PBH, with more than half of the participants experiencing no events during the treatment period. LUCIDITY is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in approximately 75 participants with PBH following Roux-en-Y gastric bypass surgery. The FDA-agreed-upon primary endpoint of LUCIDITY is reduction in the composite of Level 2 and Level 3 hypoglycemic events. Consistent reductions in composite rate of Level 2 and Level 3 hypoglycemic events also were seen with avexitide 45 mg twice daily studied in the Phase 2b trial and avexitide 30 mg twice daily and 60 mg once daily studied in the Phase 2 PREVENT trial. New pharmacokinetic (PK) and pharmacodynamic (PD) data were also presented demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period. 'Post-bariatric hypoglycemia can profoundly disrupt daily life, requiring individuals to carefully manage meals, social interactions, and routines, often while living in fear of their next hypoglycemic event. The new analysis presented at ENDO 2025 continues to support that avexitide may significantly reduce the frequency of these events,' said Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY trial and Clinical Associate Professor at Stanford University. Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, added, 'Post-bariatric hypoglycemia is a serious and underrecognized condition with no FDA-approved treatments. The data presented show that, in an exploratory analysis from the Phase 2 PREVENT and Phase 2b clinical trials, avexitide significantly reduced the composite rate of Level 2 and 3 hypoglycemic events, including at the 90 mg once daily dose that is being studied in our pivotal Phase 3 LUCIDITY trial. We are particularly encouraged that over half of participants did not experience Level 2 or Level 3 hypoglycemic events during the treatment period. In addition, the pharmacokinetic and pharmacodynamic data demonstrated continuous pharmacologic activity of avexitide 90 mg once daily dose over 24 hours. We continue to be encouraged by avexitide's potential to deliver consistent, meaningful benefit to people living with PBH.' The population PK and PD analyses presented at ENDO 2025 demonstrated that avexitide 90 mg once daily maintained consistent GLP-1 receptor inhibition from morning to midnight and between doses. In vitro potency studies showed an IC₅₀ of approximately 20-30 nM (70-100 ng/mL), indicating robust target inhibition even in the presence of significant levels of GLP-1. PK modeling demonstrated that avexitide plasma levels exceeded IC₅₀ for a full 24-hour period. LUCIDITY was informed by data from five PBH clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant and clinically meaningful reductions in hypoglycemic events. Avexitide was generally well-tolerated, with a favorable safety profile replicated across clinical trials. Completion of recruitment for LUCIDITY is expected in 2025, with a data readout anticipated in the first half of 2026 and, if approved, commercial launch anticipated in 2027. The presentation and posters are available on the ' Presentations ' tab of the Amylyx website. Webcast Information Amylyx will host an investor event today, July 13, 2025, at 6:00 p.m. PT / 9:00 p.m. ET in San Francisco to discuss post-bariatric hypoglycemia and avexitide. A live webcast of the presentation and Q&A portion of the event can be accessed under 'Events and Presentations' in the Investor section of the Company's website, The webcast will be archived and available for replay for 90 days following the event. About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 1 and Phase 2 clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent debilitating hypoglycemic events. In two Phase 2 PBH clinical trials, avexitide demonstrated highly statistically significant reductions in hypoglycemic events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living. About Post-Bariatric Hypoglycemia (PBH) Post-bariatric hypoglycemia (PBH) is a condition that is estimated to affect approximately 8% of people in the U.S. who have undergone the two most common types of bariatric surgery, sleeve gastrectomy and Roux-en-Y gastric bypass (approximately 160,000 people in the U.S.). PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. PBH can cause debilitating hypoglycemic events associated with inadequate supply of glucose to the brain, known as neuroglycopenia. Clinical manifestations can include impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability that can result in major disruptions to independent living. There are no approved therapies for PBH. About the LUCIDITY Trial LUCIDITY ( NCT06747468 ) is an approximately 75-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial includes an up to six-week screening period, including a three-week run-in period, and a 16-week double-blind treatment period. Participants who complete the double-blind period will be eligible to enter an open-label extension (OLE) period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the FDA-agreed upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Safety and tolerability will also be evaluated. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit and follow us on LinkedIn and X. For investors, please visit Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx' expectations regarding: the potential of avexitide as a treatment for PBH; expectations regarding the timing for recruitment completion and topline data readout of the Phase 3 LUCIDITY trial of avexitide in PBH; and expectations regarding timing for potential commercialization of avexitide. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx' program development activities; Amylyx' ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx' ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx' operations, as well as the risks and uncertainties set forth in Amylyx' United States Securities and Exchange Commission (SEC) filings, including Amylyx' Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. View source version on CONTACT: Media Amylyx Media Team (857) 320-6191 [email protected] Lindsey Allen (857) 320-6244 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Amylyx Pharmaceuticals, Inc. Copyright Business Wire 2025. PUB: 07/13/2025 05:00 PM/DISC: 07/13/2025 05:00 PM
Yahoo
43 minutes ago
- Yahoo
'This Isn't Jurassic Park' New Doc Explores the Science Behind the 'De-Extinction' of Dire Wolves and Other Animals
Dire wolves, the canine companions from Game of Thrones and an extinct species of the real world, are back, but how did they make their return? A new documentary plans to reveal the scientific breakthroughs that made this "de-extinction" possible. De-Extinction premieres July 17 on Curiosity Stream, and PEOPLE has a first look at the trailer for the upcoming project. The trailer for the documentary opens with a discussion of the "biodiversity problem" facing the Earth — the threat of half the world's species going extinct by 2050. Some experts who spoke with De-Extinction believe the way to combat this potential crisis is to "dig into the past and bring some of these really important species back." Colossal Biosciences is pursuing this plan, having already revived the dire wolf using grey wolf DNA, and is working on projects to bring back the giant moa bird and other extinct animals. In the trailer, the woolly mammoth and Tasmanian tiger are also mentioned as candidates for "de-extinction." The documentary promises to do more than talk about animals from the past. According to De-Extinction, the film aims to show how scientists are bringing back bygone species, and discuss the ethical dilemmas emerging from the advancement of this new field. "This isn't Jurassic Park. It's real science and real stakes, which can be much messier than people think." John Cavanagh, the doc's executive producer, teased in a statement with PEOPLE. "This is an incredible breakthrough. Genetic research has let us understand evolution like never before. De-extinction captures the potential of this moment, showing how radical science could shape the future of life on Earth. But it's also a sobering look at what's at stake," he added. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. De-Extinction will take viewers to labs around the world, where researchers are working on a variety of groundbreaking projects that they consider key to protecting the planet's biodiversity. To learn more about the science that seems straight out of science fiction, tune into De-Extinction available on Curiosity Stream starting July 17. Read the original article on People
Yahoo
an hour ago
- Yahoo
Here's the nasty reason why you should never trust the plastic hygiene liners on bathing suits
When it comes to swimwear shopping, one of the worst things you can do is try on a suit fully nude. Although bathing suit bottoms usually have a plastic hygiene liner in them — according to a microbiologist, that's the last thing you want near your privates. Nicholas Aicher is a scientist from Chicago. He took it upon himself to swab the plastic seal of two different bathing suit bottoms that hung in a retail store and place them into a petri dish to see what kind of bacteria live on them. 'I thought it would be fun for people to know all the little nastiness that we don't think about every day,' he told What's The Jam. Once home, he transferred the samples to an incubator and let them sit for a bit before revealing some shocking, gross news. The sample from one of the bathing suits had a high amount of Staphylococcus bacteria, which causes staph infections. Common symptoms of staph infections include boils and oozing blisters, and they can turn fatal if the 'bacteria invade deeper into your body, entering your bloodstream, joints, bones, lungs or heart,' according to Mayo Clinic. The results from the other sampled swimsuit were less severe, although it did have 'smaller pin-prick colonies' of the bacteria, according to Jam Press. The moral of the story is to always try on bathing suits with some sort of barrier — whether it be full coverage underwear or tight-fitting pants, like leggings — between your skin and the fabric. And bathing suits are not the only things to be wary of. A TikToker (@onenevertwhoo_one), who only wanted to be referred to by his social media handle, contracted a skin infection most likely due to never washing the clothes he bought from a thrift store, according to Jam Press. He explained in a video — that has since gone viral — that he contracted molluscum contagiosum, a viral skin infection that consists of small, raised, painless bumps on the skin. Apparently the contagious condition that spreads through either skin-to-skin contact or contact with infected objects is harmless and does not require treatment, according to NeedToKnow. Dr. Charles Puza, a board-certified NYC dermatologist, also reiterated in a TikTok video the importance of washing your clothes before putting them on, '…especially if you like fast fashion like Shein and Temu.'